- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation in Czechia
Total 8 results
-
ExelixisTakeda; Roche-GenentechActive, not recruitingMetastatic Prostate Cancer | Prostate AdenocarcinomaUnited States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Czechia, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Mexico, Poland, Portugal, Russian Federation, Singapore, Spain, ... and more
-
AmgenCompletedBone Metastases in Men With Hormone-Refractory Prostate Cancer | Bone Metastases in Subjects With Advanced Breast CancerSpain, Czechia, Peru, Russian Federation, Austria, Lithuania, Poland, South Africa, Italy, Ukraine, Israel, Argentina, Belgium, Brazil, France, Hungary, Japan, Latvia, Panama
-
AmgenCompletedBone Metastases in Men With Hormone-Refractory Prostate Cancer | Bone Metastases in Subjects With Advanced Breast Cancer | Bone Metastases in Subjects With Advanced Cancer or Multiple MyelomaUnited Kingdom, Czech Republic
-
Incyte CorporationActive, not recruitingMetastatic Merkel Cell CarcinomaUnited Kingdom, United States, Germany, Canada, Czechia, Italy, France, Spain, Switzerland, Australia, Poland, Hungary
-
Genzyme, a Sanofi CompanyActive, not recruitingMedullary Thyroid Cancer | Locally Advanced or Metastatic Medullary Thyroid CancerAustralia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czechia, Denmark, Finland, Germany, Greece, India, Israel, Italy, Korea, Republic of, Poland, Russian Federation, Sweden, United Kingdom
-
University Hospital OlomoucUniversity Hospital Ostrava; Tomas Bata Hospital, Czech Republic; General University... and other collaboratorsRecruitingCushing Syndrome | Pheochromocytoma | Adrenocortical Carcinoma | Adrenal Cortex Diseases | Adrenocortical Adenoma | Adrenal Tumor | Adrenalectomy; Status | Adrenal Mass | Adrenal Hyperplasia | Adrenal Disease | Adrenocortical Tumor | Conn Adenoma | Adrenal Gland MetastasisCzechia
-
ExelixisActive, not recruitingA Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (STELLAR-001)Renal Cell Carcinoma | Colorectal Cancer | Metastatic Castration-resistant Prostate Cancer | Hormone Receptor Positive Breast Carcinoma | Neoplasm MalignantUnited States, Australia, Belgium, Czechia, France, Germany, Italy, Netherlands, Spain, United Kingdom
-
Novartis PharmaceuticalsTerminatedMelanoma | Head and Neck Cancer | Pancreatic Cancer | Urothelial Cancer | NSCLC, Non Small Cell Lung Cancer | RCC, Renal Cell Cancer | DLBCL, Diffused Large B Cell Lymphoma | MSS, Microsatellite Stable Colon Cancer | TNBC, Triple Negative Breast Cancer | mCRPC, Metastatic Castration Resistant Prostate...Belgium, Italy, Taiwan, Germany, Spain, United States, Argentina, Australia, Austria, Czechia, France, Japan, Netherlands, Switzerland, Singapore